On 21 March, OMLYCLO received a ‘full marketing authorization’ from the European Commission(EC), almost two months after receiving a ‘recommendation for approval’ opinion from the Committee for Medicinal Products for Human Use(CHMP) of the European Medicines Agency(EMA).